Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation

Hepatology

Volumn 35, Issue 3, 2002, Pages 616-621

  Lisman, Ton ^a   Leebeek, Frank W G ^b   Meijer, Karina ^c   Van Der Meer, Jan ^c   Nieuwenhuis, H Karel ^a   De Groot, Philip G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT THROMBOPLASTIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HEMOSTASIS; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL;

EID: 0036185438     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.31771     Document Type: Article

References (36)

1. Haemostatic problems in liver disease
2. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis
3. Coagulation defects in liver disease
4. Pathophysiology and treatment of variceal hemorrhage
5. Hemostasis in liver transplantation
6. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation
7. Aprotinin and transfusion requirements in orthotopic liver transplantation: A multicentre randomised double-blind study
8. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study
9. Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices
10. Effectiveness of the recombinant factor VIIa in patients with the coagulopathy of advanced child's B and C cirrhosis
11. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: A pilot study
12. Successful use of recombinant factor VIIa in a patient with severe Haemophilia A during synovectomy
13. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors
14. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa
15. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor
16. Inhibition of thrombin generation by the zymogen factor VII: Implications for the treatment of hemophilia A by factor VIIa
17. Human monocytes support factor X activation by factor VIIa, independent of tissue factor: Implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia
18. Platelet activity of high-dose factor VIIa is independent of tissue factor
19. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe haemophilia A
20. Coagulation problems in liver disease
21. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor
22. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex
23. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor
24. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis
25. Transection of the oesophagus for bleeding oesophageal varices
26. Single bilayer vesicles prepared without sonication. Physico-chemical properties
27. Characterization of mini-protein S, a recombinant variant of protein S that lacks the sex hormone binding globulin-like domain
28. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots
29. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation
30. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis
31. Fibrinogen blocks the autoactivation and thrombin-mediated activation of factor XI on dextran sulfate
32. Hageman factor fragment inhibitor in corn seeds: Purification and characterization
33. Plasma carboxypeptidases as regulators of the plasminogen system
34. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis
35. Coagulation and fibrinolysis in orthotopic liver transplantation: Current views and insights
36. Fibrinolysis during iver transplantation in humans: Role of tissue-type plasminogen activator